Követés
Helene Karcher, PhD
Cím
Hivatkozott rá
Hivatkozott rá
Év
A three-dimensional viscoelastic model for cell deformation with experimental verification
H Karcher, J Lammerding, H Huang, RT Lee, RD Kamm, ...
Biophysical journal 85 (5), 3336-3349, 2003
2632003
Force-induced focal adhesion translocation: effects of force amplitude and frequency
PJ Mack, MR Kaazempur-Mofrad, H Karcher, RT Lee, RD Kamm
American journal of physiology-Cell Physiology 287 (4), C954-C962, 2004
972004
The “efficacy-effectiveness gap”: historical background and current conceptualization
C Nordon, H Karcher, RHH Groenwold, MZ Ankarfeldt, F Pichler, ...
Value in Health 19 (1), 75-81, 2016
932016
Role of simulation in understanding biological systems
MR Kaazempur-Mofrad, M Bathe, H Karcher, HF Younis, HC Seong, ...
Computers & structures 81 (8-11), 715-726, 2003
492003
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second …
B Amzal, S Fu, J Meng, J Lister, H Karcher
PloS one 12 (9), e0184423, 2017
472017
Exploring the molecular basis for mechanosensation, signal transduction, and cytoskeletal remodeling
MRK Mofrad, NA Abdul-Rahim, H Karcher, PJ Mack, B Yap, RD Kamm
Acta biomaterialia 1 (3), 281-293, 2005
392005
Nivolumab versus cabozantinib: comparing overall survival in metastatic renal cell carcinoma
W Wiecek, H Karcher
PLoS One 11 (6), e0155389, 2016
302016
From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics
J Yu, H Karcher, AL Feire, PJ Lowe
The AAPS journal 13 (2), 169-178, 2011
192011
A coarse-grained model for force-induced protein deformation and kinetics
H Karcher, SE Lee, MR Kaazempur-Mofrad, RD Kamm
Biophysical journal 90 (8), 2686-2697, 2006
192006
Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
C Porta, C Szczylik, R Casciano, S Fu, B Amzal, J Lister, H Karcher, ...
Critical Reviews in Oncology/Hematology 139, 143-148, 2019
102019
4 Continuum elastic or viscoelastic models for the cell
MRK Mofrad, H Karcher, RD Kamm
This page intentionally left blank, 71, 2006
92006
Proportion of women and reporting of outcomes by sex in clinical trials for Alzheimer Disease: a systematic review and meta-analysis
J Martinkova, FC Quevenco, H Karcher, A Ferrari, EC Sandset, C Szoeke, ...
JAMA Network Open 4 (9), e2124124-e2124124, 2021
62021
Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: a case study using the SOHO database
C Nordon, T Bovagnet, M Belger, J Jimenez, R Olivares, ...
Schizophrenia Research 193, 146-153, 2018
62018
Ethical and social implications of using predictive modeling for Alzheimer’s disease prevention: a systematic literature review protocol
Z Angehrn, C Nordon, A Turner, D Gove, H Karcher, A Keenan, ...
BMJ open 9 (3), e026468, 2019
32019
Predictive modelling for secondary prevention of Alzheimer’s Disease: Ethical concerns and social implications based on targeted, narrative literature review
Z Angehrn, H Karcher, FR de Vulpillieres, C Nordon
Value in Health 21, S209, 2018
32018
Cost-effectiveness in England of Cabozantinib for patients with advanced renal cell carcinoma (ARCC) after failure of prior therapy
J Lister, A Vataire, B Amzal, J Dinet, J Meng, H Karcher, S Gabriel
Value in Health 20 (9), A441, 2017
32017
Modelling decline in cognition to decline in function in Alzheimer’s disease
H Karcher, M Savelieva, L Qi, N Hummel, A Caputo, V Risson, G Capkun, ...
Current Alzheimer Research 17 (7), 635-657, 2020
22020
Ethical and Social implications of using predictive modeling for Alzheimer’s disease prevention: a systematic literature review
Z Angehrn, J Sostar, C Nordon, A Turner, D Gove, H Karcher, A Keenan, ...
Journal of Alzheimer's Disease 76 (3), 923-940, 2020
22020
The Comparative Cost-Effectiveness of Cabozantinib, Everolimus and Axitinib in Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior Therapy: Scottish Perspective
J Lister, A Vataire, B Amzal, J Dinet, J Meng, H Karcher, S Gabriel
Value in Health 20 (9), A440, 2017
22017
A model for Alzheimer’s disease in the prevention setting
A Caputo, A Racine, I Paule, C Feller, M Savelieva, N Hummel, H Karcher, ...
Value in Health 20 (9), A756, 2017
22017
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20